FDA approves Pfizer and Moderna booster doses, authorizes mix and match for COVID-19 vaccines
Author

Blaire Bryant
Upcoming Events
Related News

Key Takeaways
On October 21, the Centers for Disease Control and Prevention (CDC) endorsed the use of Moderna and Johnson & Johnson booster shots following a recommendation from the Advisory Committee on Immunization Practices’ (ACIP). The endorsement follows the Food and Drug Administration’s (FDA) October 20 announcement approving the emergency use of booster doses for both vaccines.
The CDC also endorsed the use of heterologous (mix and match) COVID-19 vaccine booster shots, following FDA approval based on safety and efficacy data. Eligible individuals will be able to select their booster dose from any of the FDA endorsed or approved COVID-19 vaccines.
Updated guidelines for the use of a COVID-19 vaccine booster dose are as follows:
- Johnson & Johnson COVID-19 vaccine: A single booster dose may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.
- Moderna COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals that are 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, or 18 through 64 years of age with frequent institutional or occupational exposure to COVID-19.
- Pfizer-BioNTech COVID-19 vaccine: A single booster dose may be administered at least six months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.
As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 190 million vaccinations in the U.S. to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 boosters, see the “Vaccine Booster Readiness Checklist for County Health Facilities” tab in NACo’s COVID-19 Vaccine Distribution Toolkit.
ADDITIONAL RESOURCES
Resource
COVID-19 Vaccine Toolkit for Counties

Related News

Engaging people with ‘lived experience’ helps build substance use disorder programming
Philadelphia’s Keli McLoyd noted to NACo's Health Steering Committee that increased harm reduction initiatives have led to fewer drug overdose deaths.

CMS announces grant awards to improve the continuity of care for justice-involved individuals
On September 27, the Centers for Medicare & Medicaid Services announced $106.5 million in state planning grants aimed at improving healthcare continuity for individuals transitioning from incarceration.

SAMHSA releases new 2024 data on rates of mental illness and substance use disorder in the U.S.
On July 28, the U.S. Department of Health and Human Services’ (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) released the findings of its annual National Survey on Drug Use and Health (NSDUH), which provides data on rates of substance use and mental illness at the national, state and local level.